TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1536399

Group type: EXPERIMENTAL
Intervention: Human albumin solution
Number of subjects: 475

Group type: COMPARATOR
Intervention: 3.5% polygeline
Number of subjects: 475
Study: 6379911

Group type: EXPERIMENTAL
Intervention: Tendamistate 400 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31166390

Group type: EXPERIMENTAL
Intervention: ECA coating on the surface before sterilization (ECA1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ECA coating after sterilization (ECA2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CG), no surface treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BisCover® coating before sterilization (DPE1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BisCover® coating after sterilization (DPE2)
Number of subjects: 48
Study: 29425211

Group type: EXPERIMENTAL
Intervention: Bioactive Food Compound (BFC) 40 g daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: No BFC consumption (Control)
Number of subjects: 180
Study: 27621610

Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 µg
Number of subjects: 3394
Study: 24750471

Group type: EXPERIMENTAL
Intervention: Implant-supported partial dentures (IRPDs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Implant-fixed partial dentures (IFPDs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Removable partial dentures (RPDs)
Number of subjects: 12
Study: 23318241

Group type: EXPERIMENTAL
Intervention: Community-based environmental management approach including provision of water container covers, clean-up campaigns, and dissemination of dengue information through schoolchildren.
Number of subjects: 4639

Group type: EXPERIMENTAL
Intervention: Community-based environmental management approach
Number of subjects: 4639

Group type: COMPARATOR
Intervention: Routine government services and some information education and communication project materials (Control)
Number of subjects: 4639
Study: 20590747

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg bid)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Voglibose (0.2 mg tid)
Number of subjects: 380
Study: 17566894

Group type: EXPERIMENTAL
Intervention: Low Carbohydrate
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Moderate Carbohydrate
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control
Number of subjects: 137
Study: 15763454

Group type: EXPERIMENTAL
Intervention: 900 mg of oral sustained-release theophylline
Number of subjects: 16
Study: 11884816

Group type: EXPERIMENTAL
Intervention: Low-dose propofol infusion (loading dose of 0.8 mg.kg(‐1) followed by continuous infusion of 30 microg.kg(‐1)min(‐1))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 90
Study: 10598888

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise training)
Number of subjects: 28
Study: 7551779

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) with active drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) with passive drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Air with active drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air with passive drainage
Number of subjects: 0
Study: 2355819

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg; nBB)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg; sBB)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg; nBB)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Beta-blockade (average of Pr, Me, and Pi)
Number of subjects: 6
Study: 367086

Group type: EXPERIMENTAL
Intervention: i.v. verapamil (0.15 mg/kg body weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oral verapamil (80 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oral verapamil (240 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oral verapamil (320 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: oral verapamil (400 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: chronic oral therapy with progressively increasing doses of verapamil
Number of subjects: 20
Study: 30683197

Group type: EXPERIMENTAL
Intervention: vonapanitase
Number of subjects: 349

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 349
Study: 28485774

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis combined with mild hypothermia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intra-arterial thrombolysis
Number of subjects: 30
Study: 26175087

Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation (200 mg iron sucrose)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation
Number of subjects: 41
Study: 23238988

Group type: EXPERIMENTAL
Intervention: Learning along a floor route
Number of subjects: 28

Group type: COMPARATOR
Intervention: Learning along a column route
Number of subjects: 28
Study: 21895505

Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 50
Study: 19139440

Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks (arm A)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks followed by IFN‐alpha‐2b 10 x 10(6) U administered subcutaneously three times a week for 48 weeks (arm B)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 353
Study: 17198093

Group type: EXPERIMENTAL
Intervention: Head neutral position
Number of subjects: 108

Group type: COMPARATOR
Intervention: Head down position
Number of subjects: 108
Study: 15098782

Group type: EXPERIMENTAL
Intervention: Polymeric surgical sealant (CoSeal)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gelfoam/thrombin (Control)
Number of subjects: 54
Study: 11514824

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure target </=80mmHg
Number of subjects: 18700

Group type: COMPARATOR
Intervention: Diastolic blood pressure target </=90mmHg
Number of subjects: 18700

Group type: EXPERIMENTAL
Intervention: Diabetic patients with diastolic pressure target </=80mmHg
Number of subjects: 18700
Study: 9781830

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained release dipyridamole (400 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and dipyridamole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7830201

Group type: EXPERIMENTAL
Intervention: Stabilization splint treatment (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study: 2533661

Group type: EXPERIMENTAL
Intervention: Peptide fraction derived from bovine factor VIII (VUEFFE‐Baldacci)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbazochrome sodium sulphate (Control)
Number of subjects: 0
Study: 412061

Group type: EXPERIMENTAL
Intervention: Oral dihydroergotamine (DHE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30583260

Group type: EXPERIMENTAL
Intervention: Approach Bias Modification (AppBM)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 131
Study: 27440869

Group type: EXPERIMENTAL
Intervention: Golimumab 100/50mg
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Golimumab 200/100mg
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Golimumab 400/200mg
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Golimumab 50mg
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Golimumab 100mg
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Golimumab (any dose)
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Golimumab 100mg with immunomodulators
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Golimumab 50mg with immunomodulators
Number of subjects: 1064
Study: 24636129

Group type: EXPERIMENTAL
Intervention: Rocker shoes
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard running shoes
Number of subjects: 13
Study: 23942480

Group type: EXPERIMENTAL
Intervention: Trauma TIPS Internet intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: No early intervention (control)
Number of subjects: 300
Study: 21571170

Group type: EXPERIMENTAL
Intervention: Layered closure
Number of subjects: 38

Group type: COMPARATOR
Intervention: Buried sutures and adhesive strips
Number of subjects: 38
Study: 19171629

Group type: EXPERIMENTAL
Intervention: Psychostimulant medications for ADHD
Number of subjects: 743

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 743
Study: 22854901

Group type: EXPERIMENTAL
Intervention: Carbamazepine up to 600 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 15699750

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 0
Study: 12617742

Group type: EXPERIMENTAL
Intervention: 80 ml contrast material injected before CT scan (group 1; n=7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 80 ml contrast material injected before CT scan (group 2; n=7)
Number of subjects: 14
Study: 10534749

Group type: EXPERIMENTAL
Intervention: Autofluorescence photodetection using violet light (lambda = 375 to 440 nm)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Spectrophotometric analysis in the green spectral range
Number of subjects: 49
Study: 8564635

Group type: EXPERIMENTAL
Intervention: 0.03% hydralazine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1% hydralazine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2108884

Group type: EXPERIMENTAL
Intervention: 1 mg/day leuprorelin given subcutaneously plus 250 mg flutamide three times a day
Number of subjects: 603

Group type: COMPARATOR
Intervention: 1 mg/day leuprorelin given subcutaneously
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Combination of leuprorelin and flutamide
Number of subjects: 603

Group type: COMPARATOR
Intervention: Leuprorelin plus placebo
Number of subjects: 603
Study: 6446008

Group type: EXPERIMENTAL
Intervention: Terbutaline 0.50 mg by aerosol inhalation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.04 mg by aerosol inhalation
Number of subjects: 20
Study: 12529069

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study: 31179798

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (25‐30 Hz, 2 mm amplitude, 10 repetitions (30‐60 s) with 1 min rest, 15‐20 min/day, 3 days/week for 24 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (medical treatment and physical therapy program)
Number of subjects: 39
Study: 31847717

Group type: EXPERIMENTAL
Intervention: 1-month treatment with inhaled budesonide (200 μg, twice daily)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 2-month treatment with inhaled budesonide (200 μg, twice daily)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 4-month treatment with inhaled budesonide (200 μg, twice daily)
Number of subjects: 101
Study: 29413236

Group type: EXPERIMENTAL
Intervention: CrossBoss catheter
Number of subjects: 246

Group type: COMPARATOR
Intervention: Wire escalation
Number of subjects: 246
Study: 27803234

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-tricalcium phosphate (HATCP) graft
Number of subjects: 11

Group type: COMPARATOR
Intervention: Autologous iliac crest bone graft (autograft)
Number of subjects: 11
Study: 25012275

Group type: EXPERIMENTAL
Intervention: Yoga practice (1 hour daily for 3 months)
Number of subjects: 3
Study: 22186772

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 0
Study: 20483664

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (100 mug)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Recombinant FSH (150 IU daily for 7 days)
Number of subjects: 396
Study: 17917554

Group type: COMPARATOR
Intervention: Risperidone alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Risperidone plus valproate
Number of subjects: 33
Study: 16271907

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone 2.5 mg/day
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 11896130

Group type: EXPERIMENTAL
Intervention: Health walks group
Number of subjects: 260

Group type: COMPARATOR
Intervention: Advice only group
Number of subjects: 260
Study: 10451805

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP), 5 mg every 8 hours for 2 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo, administered every 8 hours for 2 months
Number of subjects: 22
Study: 7598054

Group type: EXPERIMENTAL
Intervention: High-resistant starch diet (39.0 +/- 3.0 g/d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-resistant starch diet (5.0 +/- 0.4 g/d)
Number of subjects: 11
Study: 2113661

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Buserelin
Number of subjects: 32
Study: 115562

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (50 ml/kg of amino acid solution with 10 or 25 g/dl glucose plus 500 ml of soybean emulsion for 24 hours before and 5 days after operation)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 47
Study: 31353177

Group type: EXPERIMENTAL
Intervention: Spinal morphine 0.1 mg (group M+)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block using 0.3% ropivacaine (0.45 mL/kg each side, maximum 150 mg) (group pQ+)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Spinal saline (M-)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Saline (pQ-)
Number of subjects: 176
Study: 29089009

Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (coalition building)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Program technical assistance (Resources for Services)
Number of subjects: 1018
Study: 26323451

Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP) with adjunctive Tetracycline Fibers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both SRP and SRP with adjunctive Tetracycline Fibers
Number of subjects: 30
Study: 24116363

Group type: EXPERIMENTAL
Intervention: Endobon (test group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bio‐Oss (control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 22091563

Group type: EXPERIMENTAL
Intervention: Once‐yearly intravenous (IV) ZOL 5 mg
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study: 19331488

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.45 g/kg alcohol
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol (placebo)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Valid cues
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Invalid cues
Number of subjects: 22
Study: 16978883

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12950437

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reversible inhibitors of monoamine oxidase type A (RIMAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSRIs (fluvoxamine, paroxetine, sertraline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabergic drugs (clonazepam, gabapentin, pregabalin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone, tricyclics, beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine, clonazepam, sertraline, brofaromine
Number of subjects: 0
Study: 10952368

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AEX)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control
Number of subjects: 73
Study: 8778950

Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg bid)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Indomethacin (50 mg bid)
Number of subjects: 219
Study: 1862787

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 0.12 mg/kg
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 0.20 mg/kg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 6612574

Group type: EXPERIMENTAL
Intervention: One minute alcohol cleansing plus application of an antimicrobial film
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One minute alcohol cleansing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial film
Number of subjects: 0

Group type: COMPARATOR
Intervention: Five minute iodophor scrub
Number of subjects: 0
Study: 30869183

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) twice daily
Number of subjects: 543

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30) twice daily
Number of subjects: 543
Study: 28414090

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 417
Study: 26687425

Group type: EXPERIMENTAL
Intervention: Biomarker-based scoring system (TNFR1, ST2, Reg3α)
Number of subjects: 492
Study: 22941326

Group type: EXPERIMENTAL
Intervention: Office microlaparoscopic ovarian drilling (OMLOD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional laparoscopic ovarian drilling (LOD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both OMLOD and LOD
Number of subjects: 60
Study: 21463149

Group type: EXPERIMENTAL
Intervention: PCI with sirolimus‐eluting stents
Number of subjects: 600

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 600
Study: 19356233

Group type: EXPERIMENTAL
Intervention: Athletes (20 subjects)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls (18 subjects)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Athletes (20 subjects) after HG stress
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls (18 subjects) after HG stress
Number of subjects: 32
Study: 16341029

Group type: EXPERIMENTAL
Intervention: Nocturnal RigiScan
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ultrasound (MIDUS)
Number of subjects: 43
Study: 15285979

Group type: EXPERIMENTAL
Intervention: Low-dose cortisol (10 mg/day) for 1 month
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 11130086

Group type: EXPERIMENTAL
Intervention: Conveen Continence Guard (disposable vaginal device)
Number of subjects: 28
Study: 9502664

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 mcg every 4 hours until delivery)
Number of subjects: 38

Group type: COMPARATOR
Intervention: PGE2 gel (0.5 mg) followed by intravenous oxytocin infusion (Control)
Number of subjects: 38
Study: 8062778

Group type: EXPERIMENTAL
Intervention: Copper T IUD (TCu.200B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lippes loop IUD
Number of subjects: 42
Study: 2898457

Group type: EXPERIMENTAL
Intervention: BRL 26830A 50 mg qid
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31799757

Group type: EXPERIMENTAL
Intervention: Multiple counts of goblet cells from high-power fields
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: First high-power field counts
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subsequent high-power field counts
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multiple counts/individual
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Relative variability (coefficient of variation)
Number of subjects: 20
Study: 29659879

Group type: EXPERIMENTAL
Intervention: Orlistat therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: No therapy (off orlistat)
Number of subjects: 2
Study: 29132415

Group type: EXPERIMENTAL
Intervention: Verum acupuncture group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Minimal acupuncture group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (Verum and Minimal acupuncture)
Number of subjects: 42
Study: 26571891

Group type: EXPERIMENTAL
Intervention: Plum blossom needle tapping therapy at key points combined with Bobath therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bobath manipulation therapy
Number of subjects: 80
Study: 24260334

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT) - 40 sessions, 5 days/week, 60 minutes each, 100% oxygen at 1.5 ATA
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 56
Study: 21148720

Group type: EXPERIMENTAL
Intervention: rSP-C surfactant (up to eight doses administered over 96 hours)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: rSP-C surfactant
Number of subjects: 843

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 843
Study: 18655738

Group type: EXPERIMENTAL
Intervention: Hypercapnia test
Number of subjects: 103
Study: 17132834

Group type: EXPERIMENTAL
Intervention: LifeSkills Workshop + Video
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: LifeSkills Video
Number of subjects: 196

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 196
Study: 12201321

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Smoking while using OCs
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Awareness of risks of OC use and smoking
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Physicians' personal smoking habits
Number of subjects: 1139
Study: 9951781

Group type: EXPERIMENTAL
Intervention: Clodronate 100 mg i.m. every week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clodronate 100 mg i.m. every two weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clodronate (both groups)
Number of subjects: 90
Study: 8537627

Group type: EXPERIMENTAL
Intervention: Silver-impregnated cuff (Ag-CC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Routine catheter (RC) placements
Number of subjects: 101